Toby Rogers1, Adam B Greenbaum2, Vasilis C Babaliaros3, Annette M Stine4, Jaffar M Khan1, William H Schenke4, Marvin H Eng5, Gaetano Paone5, Bradley G Leshnower6, Lowell F Satler3, Ron Waksman3, Marcus Y Chen4, Robert J Lederman7. 1. Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; Medstar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC. 2. Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia; Center for Structural Heart Disease, Henry Ford Hospital, Detroit, Michigan. Electronic address: https://twitter.com/AdamGreenbaumMD. 3. Medstar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC. 4. Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. 5. Center for Structural Heart Disease, Henry Ford Hospital, Detroit, Michigan. 6. Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia. 7. Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: lederman@nih.gov.
Abstract
OBJECTIVES: This study sought to test safety and exploratory effectiveness of a dedicated transcaval closure device (TCD). BACKGROUND: Transcaval access enables delivery of large-caliber devices to the aorta in patients ineligible for transfemoral arterial access. Closure of aortocaval fistulae using off-label nitinol cardiac occluders has been shown to be safe, but persistent aortocaval fistulae at exit from the catheterization lab and bleeding complications were common in a prospective study. METHODS: Preclinical testing of the TCD was performed in 24 Yorkshire swine, including 10 under good laboratory practice conditions. Subsequently, subjects undergoing transcatheter aortic valve replacement for symptomatic severe aortic stenosis, ineligible for transfemoral arterial access, were enrolled in a U.S. Food and Drug Administration-approved early feasibility study of the TCD (Transmural Systems, Andover, Massachusetts). Independently adjudicated endpoints included technical, device, and procedural success, incorporating in-hospital and 30-day clinical and imaging follow-up. RESULTS: Transcaval access and closure in swine confirmed that at 30 days, TCDs were almost entirely endothelialized. Subsequently, 12 subjects were enrolled in the early feasibility study. Transcaval access, transcatheter aortic valve replacement, and aortocaval fistula closure was successful in all 12 subjects. The primary endpoint of technical success was met in 100% of subjects. Complete closure of the transcaval access tract was achieved in 75% of subjects at exit from the catheterization lab and in 100% of subjects at 30 days. There were zero modified Valve Academic Research Consortium-2 major vascular complications and zero Valve Academic Research Consortium-2 life-threatening or major bleeding complications related to transcaval access or the TCD. CONCLUSIONS: The TCD achieved complete closure of the transcaval access tract in most subjects at exit from the catheterization lab and essentially eliminated transcaval-related bleeding. Dedicated devices for transcaval access and closure could enable more widespread adoption of transcaval techniques without fear of bleeding complications. (Transmural Systems Transcaval Closure Device for Transcaval Access Ports During Transcatheter Aortic Valve Replacement; NCT03432494). Published by Elsevier Inc.
OBJECTIVES: This study sought to test safety and exploratory effectiveness of a dedicated transcaval closure device (TCD). BACKGROUND: Transcaval access enables delivery of large-caliber devices to the aorta in patients ineligible for transfemoral arterial access. Closure of aortocaval fistulae using off-label nitinol cardiac occluders has been shown to be safe, but persistent aortocaval fistulae at exit from the catheterization lab and bleeding complications were common in a prospective study. METHODS: Preclinical testing of the TCD was performed in 24 Yorkshire swine, including 10 under good laboratory practice conditions. Subsequently, subjects undergoing transcatheter aortic valve replacement for symptomatic severe aortic stenosis, ineligible for transfemoral arterial access, were enrolled in a U.S. Food and Drug Administration-approved early feasibility study of the TCD (Transmural Systems, Andover, Massachusetts). Independently adjudicated endpoints included technical, device, and procedural success, incorporating in-hospital and 30-day clinical and imaging follow-up. RESULTS: Transcaval access and closure in swine confirmed that at 30 days, TCDs were almost entirely endothelialized. Subsequently, 12 subjects were enrolled in the early feasibility study. Transcaval access, transcatheter aortic valve replacement, and aortocaval fistula closure was successful in all 12 subjects. The primary endpoint of technical success was met in 100% of subjects. Complete closure of the transcaval access tract was achieved in 75% of subjects at exit from the catheterization lab and in 100% of subjects at 30 days. There were zero modified Valve Academic Research Consortium-2 major vascular complications and zero Valve Academic Research Consortium-2 life-threatening or major bleeding complications related to transcaval access or the TCD. CONCLUSIONS: The TCD achieved complete closure of the transcaval access tract in most subjects at exit from the catheterization lab and essentially eliminated transcaval-related bleeding. Dedicated devices for transcaval access and closure could enable more widespread adoption of transcaval techniques without fear of bleeding complications. (Transmural Systems Transcaval Closure Device for Transcaval Access Ports During Transcatheter Aortic Valve Replacement; NCT03432494). Published by Elsevier Inc.
Entities:
Keywords:
early feasibility study; first-in-human; transcatheter aortic valve replacement; transcaval access and closure
Authors: Adam B Greenbaum; Vasilis C Babaliaros; Marcus Y Chen; Annette M Stine; Toby Rogers; William W O'Neill; Gaetano Paone; Vinod H Thourani; Kamran I Muhammad; Robert A Leonardi; Stephen Ramee; James F Troendle; Robert J Lederman Journal: J Am Coll Cardiol Date: 2016-10-29 Impact factor: 24.094
Authors: Robert J Lederman; Vasilis C Babaliaros; Toby Rogers; Annette M Stine; Marcus Y Chen; Kamran I Muhammad; Robert A Leonardi; Gaetano Paone; Jaffar M Khan; Bradley G Leshnower; Vinod H Thourani; Xin Tian; Adam B Greenbaum Journal: JACC Cardiovasc Interv Date: 2019-03-11 Impact factor: 11.195
Authors: Robert J Lederman; Adam B Greenbaum; Toby Rogers; Jaffar M Khan; Melissa Fusari; Marcus Y Chen Journal: JACC Cardiovasc Interv Date: 2017-01-09 Impact factor: 11.195
Authors: A Pieter Kappetein; Stuart J Head; Philippe Généreux; Nicolo Piazza; Nicolas M van Mieghem; Eugene H Blackstone; Thomas G Brott; David J Cohen; Donald E Cutlip; Gerrit-Anne van Es; Rebecca T Hahn; Ajay J Kirtane; Mitchell W Krucoff; Susheel Kodali; Michael J Mack; Roxana Mehran; Josep Rodés-Cabau; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys; Martin B Leon Journal: J Thorac Cardiovasc Surg Date: 2012-10-16 Impact factor: 5.209
Authors: Jaffar M Khan; Toby Rogers; Adam B Greenbaum; Vasilis C Babaliaros; Dursun Korel Yildirim; Christopher G Bruce; Daniel A Herzka; William H Schenke; Kanishka Ratnayaka; Robert J Lederman Journal: J Am Coll Cardiol Date: 2020-03-31 Impact factor: 24.094